Galena Biopharma to Report Fourth Quarter and Year End 2014 Financial Results on Thursday, March 5, 2015
February 19 2015 - 7:05AM
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company
developing and commercializing innovative, targeted oncology
therapeutics that address major medical needs across the full
spectrum of cancer care, today announced that the Company will
report its fourth quarter and year end 2014 financial results on
Thursday, March 5, 2015 after the close of the financial markets.
The company will host a conference call following the announcement
at 2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and
business results.
The conference call can be accessed by dialing (844) 825-4413
toll-free in the U.S., or (973) 638-3403 for participants outside
the U.S. The Conference ID number is: 88685732. The conference call
will also be webcast live and available under the Investors
section/Events and Presentations on the Company's website at
www.galenabiopharma.com. The archived webcast replay will be
available on the Company's website for 90 days.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical
company developing and commercializing innovative, targeted
oncology therapeutics that address major medical needs across the
full spectrum of cancer care. Galena's development portfolio ranges
from mid- to late-stage clinical assets, including a robust
immunotherapy program led by NeuVax™ (nelipepimut-S) currently in
an international, Phase 3 clinical trial. The Company's commercial
drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz®
(ondansetron) Oral Soluble Film. Collectively, Galena's clinical
and commercial strategy focuses on identifying and advancing
therapeutic opportunities to improve cancer care, from direct
treatment of the disease to the reduction of its debilitating
side-effects. For more information, visit
www.galenabiopharma.com.
CONTACT: Remy Bernarda
SVP, Investor Relations & Corporate Communications
(503) 405-8258
rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024